• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart??injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis
【24h】

Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart??injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis

机译：使用RebiSmart ？？注射装置对患者皮下注射IFN beta-1a的依从性：一项对荷兰和德国多发性硬化症患者的回顾性现实研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Long-term treatment adherence among patients with multiple sclerosis (MS) is a general concern, with an established correlation with clinical efficacy. Closely monitoring patients’ treatment behavior may have a beneficial effect on adherence. This study assessed adherence, in daily life, to subcutaneous (sc) IFN beta-1a, self-administered using the RebiSmart? electronic injection device (the IFN beta-Ia autoinjector device), in patients with MS. Patients and methods: This was a retrospective observational study analyzing treatment adherence based on injection data, eg, injection date and dose, extracted from the IFN beta-Ia autoinjector devices collected from patients in Germany and the Netherlands. Results: Data recorded in the period from 2007 to 2012 by the IFN beta-Ia autoinjector devices from 1,682 (79.7% from Germany, 20.3% from the Netherlands) patients were analyzed. A mean of 94.8% of the multi-dose cartridges (containing sc IFN beta-1a for three injections) were used completely, indicating a low incidence of application errors and drug wastage. The mean adherence rate was 90.7% and 82.9% over the entire observation period (mean treatment duration: 150.1 weeks). Median adherence rates were similar between German and Dutch patients (97.9% vs 99.0%). Conclusion: In daily clinical practice, patients using the IFN beta-Ia autoinjector device were highly adherent to sc IFN beta-1a. The injection data stored electronically in the device may help patients to adhere to treatment regimens and, if viewed by physicians, promote discussion of adherence issues with patients.
机译：目的：多发性硬化症（MS）患者的长期治疗依从性是一个普遍关注的问题，与临床疗效已建立相关性。密切监视患者的治疗行为可能会对依从性产生有益的影响。这项研究评估了MS患者在日常生活中对使用RebiSmart ？电子注射装置（IFN beta-Ia自动注射装置）自我给药的皮下（sc）IFN beta-1a的依从性。 。患者和方法：这是一项回顾性观察性研究，根据从德国和荷兰患者收集的IFNβ-Ia自动注射装置中抽取的注射数据（例如注射日期和剂量）分析治疗依从性。结果：分析了2007年至2012年期间来自IFN-β-Ia自动注射装置的1,682名患者（德国为79.7％，荷兰为20.3％）记录的数据。完全使用了94.8％的多剂量药筒（三次注射均含sc IFN beta-1a），表明使用错误和药物浪费的发生率较低。在整个观察期内，平均依从率分别为90.7％和82.9％（平均治疗时间：150.1周）。德国和荷兰患者的中位依从率相似（分别为97.9％和99.0％）。结论：在日常临床实践中，使用IFN beta-1a自动注射装置的患者对sc IFN beta-1a的依从性很高。以电子方式存储在设备中的注射数据可以帮助患者遵守治疗方案，并且，如果被医生查看，则可以促进与患者就依从性问题进行讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号